Recursion Pharmaceuticals, Inc. (BMV:RXRX)

Market Cap	32.25B -33.8%
Revenue (ttm)	1.34B +26.9%
Net Income	-11.61B
EPS	-25.94
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	187
Average Volume	1,085
Open	57.00
Previous Close	n/a
Day's Range	57.00 - 57.00
52-Week Range	56.00 - 121.50
Beta	n/a
RSI	33.12
Earnings Date	May 5, 2026

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2013
• Employees: 600
• Stock Exchange: Mexican Stock Exchange
• Ticker Symbol: RXRX

Financial Performance

In 2025, Recursion Pharmaceuticals's revenue was $74.68 million, an increase of 26.92% compared to the previous year's $58.84 million. Losses were -$644.76 million, 39.1% more than in 2024.

Financial numbers in USD